Harpoon Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics or view top-rated stocks.

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) announced its earnings results on Wednesday, November, 4th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.04. The company earned $3.89 million during the quarter, compared to analysts' expectations of $4.60 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 68.32% and a negative net margin of 434.74%.
View Harpoon Therapeutics' earnings history.

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has increased by 47.6% and is now trading at $19.29.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 1-year price objectives for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they anticipate Harpoon Therapeutics' share price to reach $31.57 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics or view top-rated stocks among Wall Street analysts.

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Harpoon Therapeutics include BioCryst Pharmaceuticals (BCRX), C4 Therapeutics (CCCC), Scholar Rock (SRRK), Translate Bio (TBIO), Sangamo Therapeutics (SGMO), Replimune Group (REPL), Forma Therapeutics (FMTX), Krystal Biotech (KRYS), Immunovant (IMVT), REGENXBIO (RGNX), Alector (ALEC), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM), Vaxcyte (PCVX) and Coherus BioSciences (CHRS).
View all of HARP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.38%), Avidity Partners Management LP (3.09%), Northern Trust Corp (0.62%), Bailard Inc. (0.54%), Charles Schwab Investment Management Inc. (0.46%) and Nuveen Asset Management LLC (0.39%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics.

HARP stock was sold by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Russell Investments Group Ltd., Northern Trust Corp, Wells Fargo & Company MN, State of Wisconsin Investment Board, and Dimensional Fund Advisors LP. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Bioventures 2014 LP Mpm, Holger Wesche, and Natalie Sacks.
View insider buying and selling activity for Harpoon Therapeutics or view top insider-selling stocks.

HARP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., GSA Capital Partners LLP, Chartwell Investment Partners LLC, Nuveen Asset Management LLC, Pura Vida Investments LLC, Bailard Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Georgia Erbez, and Gerald Phd Mcmahon.
View insider buying and selling activity for Harpoon Therapeutics or or view top insider-buying stocks.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $19.29.

Harpoon Therapeutics has a market capitalization of $489.58 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

Harpoon Therapeutics employs 77 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]